BioStock: Aptahem comments on the paused phase I study

Aptahem develops the drug candidate Apta-1 as an acute treatment of sepsis. Recently, the company announced that the ongoing phase Ia study had been temporarily paused after observing interesting data. To learn more about the significance of this data, BioStock contacted Aptahem’s CEO Mikael Lindstam.

Read the full interview with Mikael Lindstam at biostock.se:

https://www.biostock.se/en/2023/07/aptahem-comments-on-the-paused-phase-i-study/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/